Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-MUC1 CAR T cell/PD-1 knockout engineered T cell therapy - Guangzhou Anjie Biomedical Technology

Next Previous
Drug Profile

Anti-MUC1 CAR T cell/PD-1 knockout engineered T cell therapy - Guangzhou Anjie Biomedical Technology

Alternative Names: Anti-MUC1 CAR T cells and PD-1 knockout engineered T cells; Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells

Latest Information Update: 12 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Anjie Biomedical Technology
  • Developer Guangzhou Anjie Biomedical Technology; Sun Yat-Sen University; The First Affiliated Hospital of Guangdong Pharmaceutical University; University of Technology Sydney
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene silencing; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 31 May 2024 Efficacy, adverse event and pharmacokinetics data from a phase I/II trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Oesophageal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 16 Nov 2022 Sun Yat-Sen University and Guangzhou Anjie Biomedical Technology complete a phase I/II trial in Breast cancer (Late-stage disease, Recurrent, Second-line therapy or greater, Metastatic disease) in China (Parenteral) (NCT05812326)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top